STOCK TITAN

Heron Therapeutics Inc - HRTX STOCK NEWS

Welcome to our dedicated news page for Heron Therapeutics (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Heron Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Heron Therapeutics's position in the market.

Rhea-AI Summary
Heron Therapeutics, Inc. has entered into a securities purchase agreement to sell 20,734,917 shares of its common stock and pre-funded warrants to institutional investors. The purchase price for the common stock is $1.37 per share, while the pre-funded warrants have a purchase price of $1.3699 per warrant. The gross proceeds from the private placement are expected to be approximately $30.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Heron Therapeutics reported a 26% increase in net product sales for Q1 2023, reaching $29.6 million. The growth was driven by the oncology care franchise, which increased by 15%. The company also announced the appointment of Craig Collard as CEO and Jason Grillot as VP of Sales and Marketing. They plan to enhance the value of ZYNRELEF and address application issues through training. Net product sales for ZYNRELEF were $3.5 million, and for APONVIE, they were $0.3 million. The company aims to reduce cash burn and improve operational efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.22%
Tags
earnings
Rhea-AI Summary
Heron Therapeutics, Inc. will host a conference call and webcast on May 11, 2023, to report first quarter 2023 financial results and discuss recent business highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.88%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.73%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Heron Therapeutics Inc

Nasdaq:HRTX

HRTX Rankings

HRTX Stock Data

411.90M
122.09M
0.89%
76.09%
16.35%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About HRTX

heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.